|
|
||||||||
|
|
|||||||||
|
|
Neurosciences: Basic ScienceEmerging Ligands and Targets |
1 Radiology, Johns Hopkins Medicine, Baltimore, Maryland; 2 NIDA, NIH, Baltimore, Maryland
516
Objectives: The currently available radioligands for PET imaging of nAChR in humans, 2-[18F]FA and 6-[18F]FA, exhibit slow brain kinetics. As the result, PET studies with these radioligands are logistically impractical for many imaging centers. Here we introduce [18F]JHU87522 (JHU), a novel, high affinity nAChR PET radioligand with rapid brain kinetics and high binding potentials (see synthesis in Gao et al., this meeting.
Methods: Regional brain distribution, blockade, metabolism and toxicology of JHU have been done in mice and baboon. A functional assay was performed at the SH-EP1 cells stably expressing human
4β2-nAChR.
Results: Rapid and high uptake of radioactivity in the baboon brain regions (peak in the thalamus (Th) is at 7-30 min, 600%SUV) with robust washout thereafter was seen after the bolus injection of JHU. The regional brain distribution of radioactivity was similar to those of 2-[18F]FA and 6-[18F]FA. PET modeling demonstrated that only 90 min of scanning was needed for accurate determination of the binding potential values (BPTh=4.8) versus 6-7 h for [18F]FA (BPTh=2). In the baboon blockade study with cytisine (2 mg/kg, s.c.) there was a 93% reduction of radioactivity in Th, the region with high density of nAChR. The toxicology study in mice showed that JHU exhibits lower toxicity than 2-FA. The functional assay proved that JHU is an antagonist for
4β2-nAChR.
Conclusions: JHU exhibits rapid brain kinetic, high binding potentials and brain uptake and a good safety profile. It holds promise as a superior substitute of 2-[18F]FA and 6-[18F]FA for studying nAChR in the human brain by PET.
Research Support: JHU Radiology, NIH grant R21MH079017
| ||||||||||||||||||||||||||||||||||||||